REG - Oxford Biomedica PLC - Result of Annual General Meeting

Oxford BioMedicaAnnouncement

24/06/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240624:nRSX6676Ta&default-theme=true

RNS Number : 6676T  Oxford Biomedica PLC  24 June 2024

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 24 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a quality and innovation-led cell and gene therapy CDMO,
today announces that  all resolutions proposed were duly passed at its Annual
General Meeting (AGM), held at 3pm on 24 June 2024 in Oxford. As proposed in
the Notice of AGM, all resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by
visiting the Company's website at www.oxb.com (http://www.oxb.com)

 

Copies of the document setting out the above resolutions passed at the 2024
AGM have been submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

On the Record Date (20 June 2024) there were 105,268,630 ordinary shares of 50
pence each in issue, each carrying one vote per share.

 

                                                                                                                                                                                                                 Result

                                                                                       Votes                                                              Votes                         Votes       Total

                                                                                       For (incl. votes at the Chairman's discretion)                     Against     % of votes cast   Withheld*   votes cast

      Resolution                                                                                                                        % of votes cast

      Ordinary resolutions

      To receive and adopt the Company's Annual Report and accounts for the            72,477,617                                       99.99%            4,552       0.01%             608,560     72,482,169   PASS

    financial year ended 31 December 2023, the Directors' Report, and the Report

      of the Independent Auditors on those accounts and reports.

 1

      To receive the Directors' Remuneration Report and the Report of the              72,347,034                                       99.61%            280,462     0.39%             463,233     72,627,496   PASS

    Independent Auditors on the auditable part of the Remuneration Report

      (excluding the Directors' Remuneration Policy) for the financial year ended 31

    December 2023.

 2

      To consider and, if thought fit, approve the Directors' Remuneration Policy,     70,899,498                                       97.67%            1,691,080   2.33%             500,151     72,590,578   PASS

    the full text of which is included in the Directors' Remuneration Report for

      the financial year ended 31 December 2023.

 3

      To appoint Peter Soelkner as a Director of the Company.                          72,622,493                                       99.98%            11,817      0.02%             456,419     72,634,310   PASS

 4

      To reappoint Dr. Roch Doliveux as a Director of the Company.                     72,614,517                                       99.97%            18,800      0.03%             457,412     72,633,317   PASS

 5

      To reappoint Stuart Henderson as a Director of the Company.                      72,621,001                                       99.98%            13,309      0.02%             456,419     72,634,310   PASS

 6
      To reappoint Professor Dame Kay Davies as a Director of the Company.             72,619,922                                       99.98%            13,395      0.02%             457,412     72,633,317   PASS

 7

      To reappoint Dr. Frank Mathias as a Director of the Company.                     72,623,288                                       99.99%            10,522      0.01%             456,919     72,633,810   PASS

 8

      To reappoint Stuart Paynter as a Director of the Company.                        72,623,118                                       99.99%            10,199      0.01%             457,412     72,633,317   PASS

 9

      To reappoint Robert Ghenchev as a Director of the Company.                       72,585,321                                       99.93%            47,996      0.07%             457,412     72,633,317   PASS

 10

      To reappoint Namrata Patel as a Director of the Company.                         72,619,735                                       99.98%            13,582      0.02%             457,412     72,633,317   PASS

 11

      To reappoint Leone      Patterson as a Director of the Company.                  71,427,129                                       98.34%            1,206,006   1.66%             457,594     72,633,135   PASS

 12

      To reappoint Dr. Heather Preston as a Director of the Company.                   71,207,370                                       98.04%            1,425,964   1.96%             457,395     72,633,334   PASS

 13

      To appoint PricewaterhouseCoopers LLP as auditors of the Company from the        72,579,009                                       99.98%            16,159      0.02%             495,561     72,595,168   PASS

    conclusion of the meeting until the conclusion of the next AGM of the Company

      at which the accounts are laid.

 14

      To authorise the Audit Committee for and on behalf of the Board to determine     72,580,492                                       99.98%            15,389      0.02%             494,848     72,595,881   PASS

    the auditor's remuneration.

 15

      To approve the Oxford Biomedica 2024 Long Term Incentive Plan.                   62,538,002                                       86.10%            10,095,007  13.90%            457,720     72,633,009   PASS

 16
      To approve the Oxford Biomedica 2024 Deferred Bonus Plan.                        62,775,222                                       86.43%            9,856,415   13.57%            459,092     72,631,637   PASS

 17

      To approve the Oxford Biomedica 2024 Sharesave Scheme.                           63,225,470                                       87.05%            9,408,593   12.95%            456,666     72,634,063   PASS

 18

      To authorise the Directors to allot shares.                                      72,168,633                                       99.41%            426,961     0.59%             495,135     72,595,594   PASS

 19

      To authorise the Directors to disapply pre-emption rights.                       72,215,940                                       99.48%            378,341     0.52%             496,448     72,594,281   PASS

 20

      To authorise the Directors to further disapply pre-emption rights for            72,215,440                                       99.48%            378,841     0.52%             496,448     72,594,281   PASS

    acquisitions and specified capital investments.

 21

      To permit the Directors to convene general meetings (other than annual general   72,369,632                                       99.63%            265,377     0.37%             455,720     72,635,009   PASS

    meetings) on not less than 14 days' notice.

 22

 

* A vote withheld is not a vote in law and is not counted towards votes cast
in respect of a resolution.

 

 

 

 

 

 

 

 

In addition, further to the announcement by the Company on 11 March 2024, Dr.
Michael Hayden and Catherine Moukheibir have stepped down from the Company's
Board of Directors with effect from the conclusion of today's AGM.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

ABOUT OXFORD BIOMEDICA

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKQBQABKDDAB